Cereno Scientific (DB:4A1) - Prezzo delle azioni, notizie e analisi

4A1 Panoramica delle azioni

Cereno Scientific AB (publ), società di biotecnologie in fase clinica, sviluppa terapie per il trattamento di malattie cardiovascolari e rare in tutto il mondo. Maggiori dettagli

4A1 analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Analisi del rischio

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Ha meno di 1 anno di pista di cassa

Gli utili sono diminuiti del 49.7% all'anno negli ultimi 5 anni

Gli azionisti sono stati diluiti nell'ultimo anno

Cereno Scientific AB (publ) Concorrenti

Heidelberg Pharma

XTRA:HPHA

€105.8m

2invest

XTRA:2INV

€62.7m

Formycon

XTRA:FYB

€857.2m

Biotest

XTRA:BIO3

€1.3b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Cereno Scientific
Prezzi storici delle azioni
Prezzo attuale dell'azione	SEK 0.43
Massimo di 52 settimane	SEK 0.79
Minimo di 52 settimane	SEK 0.29
Beta	0.35
1Variazione di 1 mese	-10.22%
Variazione a 3 mesi	-25.80%
Variazione di 1 anno	-0.23%
3Variazione a 3 anni	-8.37%
Variazione a 5 anni	n/a
Variazione dall'IPO	50.35%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	4A1	DE Biotechs	DE Mercato
7D	2.7%	0.8%	0.8%
1Y	-0.2%	-18.3%	8.6%

Ritorno vs Industria: 4A1 ha superato il German Biotechs che ha restituito -18.3 % nell'ultimo anno.

Rendimento vs Mercato: 4A1 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 8.6 % nell'ultimo anno.

Volatilità dei prezzi

Is 4A1's price volatile compared to industry and market?
4A1 volatility
4A1 Average Weekly Movement	11.6%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di 4A1 è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 12% ) di 4A1 è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2012	5	Sten Sorensen	www.cerenoscientific.com

Cereno Scientific AB (publ), società di biotecnologie in fase clinica, sviluppa terapie per il trattamento di malattie cardiovascolari e rare in tutto il mondo. Il candidato farmaco principale dell'azienda è il CS1, un prodotto in fase II di sperimentazione clinica per il trattamento della malattia rara dell'ipertensione arteriosa polmonare, nonché un inibitore dell'istone deacetilasi (HDAC) che agisce come modulatore epigenetico con proprietà di riduzione della pressione, rimodellamento inverso, antinfiammatorie, antifibrotiche e antitrombotiche. I suoi candidati farmaci preclinici comprendono CS585 e CS014, in fase pre-clinica per il trattamento delle malattie cardiovascolari.

Cereno Scientific AB (publ) Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Cereno Scientific con la sua capitalizzazione di mercato?
4A1 statistiche fondamentali
Capitalizzazione di mercato	€121.70m
Guadagni(TTM)	-€7.03m
Ricavi(TTM)	€7.52m

16.2x

Rapporto P/S

-17.3x

Rapporto P/E

4A1 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
4A1 Conto economico (TTM)
Ricavi	SEK 86.75m
Costo del fatturato	SEK 0
Profitto lordo	SEK 86.75m
Altre spese	SEK 167.87m
Guadagni	-SEK 81.12m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

Feb 25, 2025

Utile per azione (EPS)	-0.29
Margine lordo	100.00%
Margine di profitto netto	-93.51%
Rapporto debito/patrimonio netto	39.2%

Come si è comportato 4A1 nel lungo periodo?

Vedi performance storica e confronto

4A1 Panoramica delle azioni

Analisi del rischio

Cereno Scientific AB (publ) Concorrenti

XTRA:HPHA

€105.8m

XTRA:2INV

€62.7m

XTRA:FYB

€857.2m

XTRA:BIO3

€1.3b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Cereno Scientific Announces Initiation of Multiple Ascending Dose (MAD) Part of Phase I Trial of the Novel HDAC Inhibitor CS014

Cereno Scientific AB (publ) to Report Q2, 2025 Results on Aug 27, 2025

Cereno Scientific AB (publ) Selects Rare Disease Idiopathic Pulmonary Fibrosis as the Initial Target Indication for Novel HDACi CS014

Cereno Scientific AB (publ) Announces New Preclinical Data Demonstrates Dose Dependent Positive Impact on Reversal of Pulmonary Vascular Remodeling

Cereno Scientific AB Announces Changes in the Nomination Committee's Composition for the Annual General Meeting 2025

No independent directors

Recent updates

Cereno Scientific Announces Initiation of Multiple Ascending Dose (MAD) Part of Phase I Trial of the Novel HDAC Inhibitor CS014

Cereno Scientific AB (publ) to Report Q2, 2025 Results on Aug 27, 2025

Cereno Scientific AB (publ) Selects Rare Disease Idiopathic Pulmonary Fibrosis as the Initial Target Indication for Novel HDACi CS014

Cereno Scientific AB (publ) Announces New Preclinical Data Demonstrates Dose Dependent Positive Impact on Reversal of Pulmonary Vascular Remodeling

Cereno Scientific AB Announces Changes in the Nomination Committee's Composition for the Annual General Meeting 2025

No independent directors

Cereno Scientific AB Announces New Preclinical Data for Cereno Scientific's Novel IP Receptor Agonist CS585 Presented at ESC Congress 2024

Cereno Scientific Receives Orphan Medicinal Product Designation in the Eu for Cs1 in Rare Disease Pulmonary Arterial Hypertension

Cereno Scientific AB (publ), Annual General Meeting, Jun 17, 2025

Cereno Scientific Expands Patent Protection for PAH Drug Candidate CS1's Third Patent Family in Brazil

First Subject Dosed in Cereno Scientifics First-In-Human Phase I Trial of Novel Hdac Inhibitor Cs014

Cereno Scientific Receives Approval from, EMA to Initiate First-In-Human Phase I Trial with Novel Epigenetic HDAC Inhibitor, CS014

Cereno Scientific AB (publ) to Report Q1, 2025 Results on May 22, 2025

Cereno Scientific AB (Publ) Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025

Cereno Scientific AB (publ), Annual General Meeting, Apr 16, 2024

Cereno Scientific AB (Publ) Approves Election of New Directors

Cereno Scientific AB Submits Clinical Trial Application (CTA) for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH

Cereno Scientific Appoints Don De Bethizy as Board of Directors

Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH

Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH

New minor risk - Market cap size

Cereno Scientific AB Appoints Rahul Agrawal as Chief Medical Officer and Head of R&D

Cereno Scientific AB (publ) Appoints Megha Ranjan as Project Director to Strengthen Business Capabilities

Cereno Scientific AB Appoints Julia Fransson as Director of Business Development

Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension

Cereno Scientific Strengthens R&D with Recruitment of Tatiane Abreu Dall'Agnol as Medical Director

Cereno Scientific AB Confirms New Clinic Activated in the Phase II Study of Drug Candidate CS1 in Rare Disease PAH

Cereno Scientific AB (publ) to Report Q3, 2024 Results on Nov 21, 2024

Cereno Scientific's Novel HDACi CS014 Has Potential to Become an Effective Antithrombotic Therapy in Patients with A High Risk of Thrombotic Events as Presented at the ASH Meeting

Cereno Scientific Announces New Preclinical Data Concludes That Drug Candidate CS585

Cereno Scientific Completes Preclinical Safety Program for Innovative Drug Candidate CS014 Targeting Thrombosis Prevention and Reaches A Major Preparatory Milestone Towards the Phase I Study

Cereno Scientific Obtains First Patent in India for Drug Candidate Cs1 Through Its Third Patent Family

Cereno Scientific AB (Publ) Move to Request “Compassionate Use” of CS1 for Treatment of Patients with Rare Disease PAH

Third quarter 2023 earnings released

Cereno Scientific Reports Significant Progress and A Time Time Adjustment in the Phase II Study of CS1 in Rare Disease PAH

Cereno Scientific AB (publ) Appoints Jeppe Øvlesen as a New Board Member

Cereno Scientific AB (Publ) Reports Positive Results from the Data Quality Control Review Initiative in the Phase II Study of CS1 in Rare Disease Pul Arterial Hypertension (PAH)

Cereno Scientific Announces Appointments to the Nomination Committee Ahead of the Annual General Meeting 2024

New major risk - Shareholder dilution

Second quarter 2023 earnings released

Cereno Scientific to Open Two New Clinics to Complete Patient Recruitment in the Phase II Study of CS1 in Pah

Cereno Scientific AB (Publ) Appoints Eva Jagenheim as Chief Financial Officer

Cereno Scientific Reports Positive Data from Patient Case Study

Chairperson recently bought €68k worth of stock

Cereno Scientific Reports an Investigator-Initiated Patient Case Study from the Ongoing Phase II Study of CS1 in PAH

Cereno Scientific AB (publ), Annual General Meeting, Jun 03, 2024

Cereno Scientific Shares Progress Update in the Phase II Study with Drug Candidate CS1 in the Rare Disease PAH

Cereno Scientific's Phase II Study in the Rare Disease PAH Reports Two Patients Successfully Completed the Treatment Period with Drug Candidate CS1

Full year 2022 earnings released: kr0.20 loss per share (vs kr0.15 loss in FY 2021)

Full year 2022 earnings released: kr0.26 loss per share (vs kr0.15 loss in FY 2021)

Cereno Scientific AB (publ) Reports Progress with CS1 Phase II Study in Pulmonary Arterial Hypertension

Cereno Scientific AB (publ) to Report Nine Months, 2023 Results on Nov 17, 2023

Cereno Scientific AB (Publ) Appoints Etienne Adriansen to Chief Business Officer, as of March 1, 2023

Cereno Scientific Announces Changes in the Executive Management Team

Cereno Scientific Reports Six Activated Clinical Sites and Updated Timeline in the Phase II Study in PAH with Drug Candidate CS1

Cereno Scientific AB (Publ) Announces Appointment of Nomination Committee